Literature DB >> 11079018

Performance characteristics of the Becton Dickinson ProbeTec System for direct detection of Chlamydia trachomatis and Neisseria gonorrhoeae in male and female urine specimens in comparison with the Roche Cobas System.

E L Chan1, K Brandt, K Olienus, N Antonishyn, G B Horsman.   

Abstract

OBJECTIVE: The Becton Dickinson BDProbeTec ET System is a new semiautomated system using strand displacement amplification technology that simultaneously amplifies and detects Chlamydia trachomatis and Neisseria gonorrhoeae DNA. The strand displacement amplification products are hybridized with a fluorescent detector probe and are captured by a chemiluminescent assay in a microwell format. An amplification control is also included to monitor assay inhibition. This study evaluated the performance of the BDProbTec ET system in detecting C trachomatis and N gonorrhoeae in male and female urine specimens, calculated its ability to process large volumes of specimens, and determined the inhibition rate.
MATERIALS AND METHODS: Eight hundred twenty-five male and 399 female urine specimens were tested for both C trachomatis and N gonorrhoeae with the BDProbeTec ET system, and results were compared with those of the Roche Amplicor Cobas system. All urine specimens were processed on both assays on the same day they were received, according to the manufacturers' instructions. Discrepant results were resolved by in-house polymerase chain reaction assays. Internal or amplification controls were also used in each specimen assay to monitor inhibition. The throughput of the BDProbTec ET system was further tested with 150 urine specimens on an 8-hour shift for 2 days.
RESULTS: The overall sensitivity, specificity, positive predicative value, and negative predicative value for for detection of chlamydia were 95.3%, 99.3%, 95.9%, and 99.2% for strand displacement amplification and 95.9%, 98.3%, 90.6%, and 99.3% for the Roche Amplicor system. For detection of gonorrhea, these values were 100%, 99.7%, 88.2%, and 100% and 96.7%, 98.9%, 69%, and 99.9%, respectively. The overall inhibition rates for both strand displacement amplification and Roche Amplicor were less than 3.5%. The BDProbTec ET system was able to produce 150 results each for chlamydia and gonorrhea and the internal control within the 8-hour shift.
CONCLUSIONS: The performance characteristics of the BDProbeTec ET assay are similar to those of the Roche Amplicor polymerase chain reaction for detection of chlamydia and gonorrhea in male and female urine specimens. The system was able to produce 300 results in an 8-hour shift.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079018     DOI: 10.5858/2000-124-1649-PCOTBD

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  13 in total

Review 1.  Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge.

Authors:  David M Whiley; John W Tapsall; Theo P Sloots
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  The laboratory diagnosis of Neisseria gonorrhoeae.

Authors:  Lai-King Ng; Irene E Martin
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-01       Impact factor: 2.471

3.  Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species.

Authors:  Sepehr N Tabrizi; Magnus Unemo; Athena E Limnios; Tiffany R Hogan; Stig-Ove Hjelmevoll; Susanne M Garland; John Tapsall
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

4.  Vulvovaginal-swab or first-catch urine specimen to detect Chlamydia trachomatis in women in a community setting?

Authors:  Sue Skidmore; Paddy Horner; Alan Herring; Joanne Sell; Ian Paul; Jane Thomas; E Owen Caul; Matthias Egger; Anne McCarthy; Emma Sanford; Chris Salisbury; John Macleod; Jonathan A C Sterne; Nicola Low
Journal:  J Clin Microbiol       Date:  2006-10-25       Impact factor: 5.948

5.  Use of pooled urine samples and automated DNA isolation to achieve improved sensitivity and cost-effectiveness of large-scale testing for Chlamydia trachomatis in pregnant women.

Authors:  G I J G Rours; R P Verkooyen; H F M Willemse; E A E van der Zwaan; A van Belkum; R de Groot; H A Verbrugh; J M Ossewaarde
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Aptima Combo 2 testing detected additional cases of Neisseria gonorrhoeae infection in men and women in community settings.

Authors:  Julius Kapala; Kathy Biers; Michael Cox; Margaret Kamionka; Jeff Sumner; Ramandeep Toor; Jodi Gilchrist; Dan Jang; Marek Smieja; Max Chernesky
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

7.  High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay.

Authors:  Max Chernesky; Dan Jang; Kathy Luinstra; Sylvia Chong; Marek Smieja; Wenjie Cai; Beth Hayhoe; Eder Portillo; Cindy Macritchie; Cheryl Main; Ruth Ewert
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

8.  External quality assessment for detection of Chlamydia trachomatis.

Authors:  V J Chalker; H Vaughan; P Patel; A Rossouw; H Seyedzadeh; K Gerrard; V L A James
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Decline in the prevalence of HIV and sexually transmitted infections among female sex workers in Benin over 15 years of targeted interventions.

Authors:  Luc Béhanzin; Souleymane Diabaté; Isaac Minani; Marie-Claude Boily; Annie-Claude Labbé; Clément Ahoussinou; Séverin Anagonou; Djimon M Zannou; Catherine M Lowndes; Michel Alary
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

10.  Urine based screening for asymptomatic/undiagnosed genital chlamydial infection in young people visiting the accident and emergency department is feasible, acceptable, and can be epidemiologically helpful.

Authors:  T Aldeen; A Haghdoost; P Hay
Journal:  Sex Transm Infect       Date:  2003-06       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.